Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.
Anthony M HunterHannah NewmanAmy E DezernDavid P SteensmaSandrine NiyongereGail J RobozQianxing MoOnyee ChanAaron GerdsDavid A SallmanWilliam Dominguez-ViqueiraChristopher LetsonMaria E BalasisMarkus BallTraci KruerHailing ZhangJeffrey E LancetAlan F ListMikkael A SekeresRami S KomrokjiEric PadronPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Ruxolitinib demonstrated clinical efficacy and an acceptable adverse event profile in patients with CMML, identifying a potential novel therapeutic in this rare malignancy. Furthermore, this study demonstrates proof of concept that PDX modeling can recapitulate responses of patients treated on clinical trial and represents a novel correlative study that corroborates clinical efficacy seen in humans.See related commentary by Shastri and Adrianzen-Herrera, p. 6069.